COMP <GO>
WST vs RMD // 10Y YIELD & FRED MACRO BETA
West Pharmaceutical Services Inc. (NYSE) VS. ResMed Inc. (NYSE) • 15-METRIC TALLY: WST 3
— RMD 10
▲ 10Y YIELD & FRED MACRO BETA LEADER: WST
LAST: $412.62 (-0.97%) • MKT CAP: $29.32B
macro-sensitivity
1.08
LAST: $229.94 (-9.05%) • MKT CAP: $35.56B
macro-sensitivity
0.93
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (WST VS. RMD)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | WST | RMD | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 35.90% | 59.40% | -23.50 | RMD | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 17.90% | 22.90% | -5.00 | RMD | /roic <GO> |
| EV/EBITDA & P/E Valuation | 34.7x | 19.9x | +14.80 | RMD | /valuation <GO> |
| Free Cash Flow Yield | 1.60% | 4.67% | -3.07 | RMD | /fcf-yield <GO> |
| Operating Margin | 19.00% | 32.70% | -13.70 | RMD | /operating-margins <GO> |
| Net Profit Margin | 16.10% | 27.20% | -11.10 | RMD | /net-margins <GO> |
| Revenue Growth (YoY) | 6.30% | 9.80% | -3.50 | RMD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.21% | 0.87% | -0.66 | RMD | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 19.06 | 12.49 | +6.57 | WST | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 9/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 77.0 | 60.1 | +16.90 | WST | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 1.08 | 0.93 | +0.15 | WST | /macro-sensitivity <GO> |
| Forward P/E Multiple | 55.2x | 23.6x | +31.60 | RMD | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $29.32B | $35.56B | -$6.23B | RMD | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | WST REV | RMD REV | WST GROSS % | RMD GROSS % | WST FCF | RMD FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.07B | $5.15B | 35.9% | 59.4% | $468.9M | $1.66B |
| FY 2024 | $2.89B | $4.69B | 34.5% | 56.7% | $276.4M | $1.30B |
| FY 2023 | $2.95B | $4.22B | — | — | $643.8M | $503.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
WST // BETA 1.08
RMD // BETA 0.93